Yeji
CRLconf 0.85

reproxalap — CRL

$ALDX · Aldeyra Therapeutics, Inc. · dry eye disease
Event date
Date TBD
Sponsor runway
38 mo
$65.0M liquid

Evidence

Aldeyra Received a Complete Response Letter for Reproxalap for the Treatment of Dry Eye Disease The letter stated that the NDA did not demonstrate "efficacy in treating ocular symptoms associated with dry eyes" and that "at least one additional adequate and well-controlled study to demonstrate a positive effect on the treatment of ocular symptoms of dry eye" should be conducted.
Source: Press release · 2023-11-28View press release ↗

Comparable historical crls· last 5 years · same event type

No comparable historical outcomes in our database yet — backfill of past readouts arrives next ingestion cycle.

Recent insider activity· ±90 days

No insider Form 4 activity reported on $ALDX in the 90 days around this event.